Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aromatase (P450AROM) is the enzyme complex with converts testosterone to estradiol and androstendione to estrone. This enzyme was detected in various normal tissues and uterine pathology such as uterine myoma, endometrial cancer and endometriosis. The aim of the study was to estimate expression of P450AROM messenger ribonucleic acid (mRNA) in normal, hyperplastic and malignant endometrium, and the ability to convert androstenedione to estrone by endometrial cancer tissue. Normal endometrium was obtained from 16 (12 proliferative phase, 4 secretory phase) regularly cycling women after hysterectomy for myomas, hyperplastic endometrium (n = 5) and endometrial cancer (n = 5) from postmenopausal women. The ability to convert androstenedione to estrone was estimated in 16 cases of endometrial cancer in postmenopausal women. P450AROM mRNA was measured by a quantitative assay based on reverse transcribing the mRNA into cDNA with reverse transcriptase (RT) then amplification of the cDNA using the polymerase chain reaction (PCR). The mean (+/- SEM) expression of aromatase gene in proliferative endometrium was 84.4 +/- 14.0 pg mRNA/microgram DNA and in secretory endometrium 200.3 +/- 87.8 pg mRNA/microgram DNA. The mean (+/- SEM) P450AROM mRNA expression in endometrial hyperplasia was 92.9 +/- 17.8 pg mRNA/microgram DNA, in endometrial cancer was 14.3 +/- 7.7 pg mRNA/microgram DNA. Androstenedione to estrone conversion in endometrial cancer tissue culture was 252.5 +/- 91 fmol/g tissue/h. Our data confirm that human normal, hyperplastic and malignant endometrium do express P450AROM mRNA and that aromatase activity is present in endometrial cancer tissue.
Ginekol Pol 2000 Mar
PMID:[Aromatase (P450AROM) mRNA expression in normal, hyperplastic and malignant endometrium and aromatase activity in endometrial cancer tissue culture]. 1084 13

The aim of our study was to comparison of a thickness of endometrium and blood flow parameters measured by transvaginal ultrasonography with color and "power" angio Doppler. We examined 81 women in perimenopausal period. Blood flow characteristics and histopathological changes were evaluated. There were no endometrial changes in 34 women. We detected 22 perimenopausal women and 12 postmenopausal with endometrial hyperplasia. In 13 cases we find endometrial carcinoma, 10 in postmenopausal women. Transvaginal ultrasonography with color Doppler can be using to diagnose pathology of endometrium providing that all suspicious images will be verified by other more invasive method.
Ginekol Pol 2000 Sep
PMID:[Ultrasonographic detection of endometrial thickness and uterine blood flow in perimenopausal women]. 1108 7

The aim of this study was to investigate the useful of colour flow doppler (CDF) and hysteroscopy to determine the endometrium status in endometrial cancer patients who were treated by radiotherapy alone. The study group comprised 33 patients. There were hysteroscopy and CDF performed in obligatory regular periods. High useful of hysteroscopy was confirmed. It appeared 89% of sensitivity and 91% of specificity. CDF sensitivity was 69% and specificity 75%. Absence of the flow signal in endometrial tissue was correlated with no of malignant pathology in uterus. Pulsatility and resistance indexes in CDF were not characterised for histopathology status of endometrium.
Ginekol Pol 2001 Apr
PMID:[Evaluation of the value of hysteroscopy or doppler ultrasonography for monitoring treatment effects of radiotherapy in patients with cervix carcinoma]. 1144 75

Authors presents the risk factors in endometrial cancer underlying such problems like hyperestrogenism, both external and internal caused by hormonally active ovarian masses, polycystic ovarian syndrome, adrenocortical hyperfunction and role of obesity in this pathological state. Other factors have been also described diabetes mellitus and hypertension, oral contraception, genetics factors, patient's obstetric history and other diseases where the increase of aromatization activity of androstendion to estron has been noted.
Ginekol Pol 2001 Dec
PMID:[The risk factors of endometrial cancer]. 1188 89

The morphometric estimation of the influence of the caproate 17-alfa-hydroxyprogesterone on the endometrial cancer was the aim this work. The quantitative evaluation of the reaction of neoplasmatic and some stromal cells such as fibroblast, fibrocytes, lymphocytes, macrophages was carried out. Every patient was given a high doses of the medicine before the operation. The comparison of the histological image and than morphometric estimation was done after operation. Examination was performed in three separate groups depending on the grading of the tumor. The result was the decreased number of the neoplasmatic cells in every group independently on the grading. In the fibroblasts and fibrocytes groups the increased number of cells especially in the G1 and G2 group was observed. In the group of lymphocytes and macrophages the increased number of all cells was observed in every group. On the basic of our results we assume that the application of the high doses of progestins decreased number of neoplasmatic cells and stimulates the cells of the monocyte-macrophage system.
Ginekol Pol 2001 Dec
PMID:[The effect of progestins on endometrial cancer in morphometric evaluation]. 1188 93

Gynaecologic malignant neoplasms are significant medical and social problem in Poland. The majority of Polish women suffer from breast, cervix, ovary and endometrial cancer. This paper shows common and new methods in early diagnosis of neoplasmic diseases.
Ginekol Pol 2001 Dec
PMID:[Early diagnosis of gynaecologic and breast cancers]. 1188 98

In the current study, PCNA and p53 proteins were immunohistochemically studied in the proliferative (n = 5), hyperplastic (n = 4) and neoplastic (n = 20) human endometrium. PCNA immunostaining was noted in 2 out of 5 (40%) proliferative, 4 out of 4 (100%) hyperplastic, and in 18 out of 20 (90%) neoplastic slides. Concomitant PCNA and p53 expression was reported in 12 out of 20 (60%) malignant tumors. All non-endometrioid neoplasms were PCNA-positive, suggested this proliferative marker is commonly expressed in the unfavorable histological types of endometrial cancer.
Ginekol Pol 2001 Dec
PMID:[Assessment of the PCNA and P53 proteins expression in the proliferative, hyperplastic and neoplastic human endometrium]. 1188 13

It's a review of literature on the clinical effects of Livial. Livial (generic name-tibolone) makes a therapy of choice for postmenopausal women. It's a synthetic steroid with estrogenic, progestagenic and androgenic properties due to its tissue specific effects. Livial is effective in reducing wasomotors symptoms and has positive effects on mood and libido. It also prevents bone loss and reduces risk of fractures. Livial is safe for cardiovascular system. The incidence of side effects is very low, about 3 in every one hundred. Because of its progestagenic activity in endometrium it results in endometrial atrophy but in vagina the studies showed oestrogen--like effects, i.e. improvement in vaginal dryness. Livial may be used as an "add-back" therapy in conjunction with GnRH agonists treatment. The rates of discontinuation is lower than HTR preparations, about 25%. Livial may have benefits over conventional HRT in older women (over 65 years old), in women with history of endometrial cancer, breast cancer and endometriosis.
Ginekol Pol 2002 Mar
PMID:[Clinical aspects of Livial in postmenopausal replacement therapy]. 1209 55

Reports on coexistence of the three cancers: a carcinoid of the appendix, myoma of the uterus and adenoma of the uterine cavity occurring in a female patient are exceptionally rare. Such a case may occur with a frequency of 2 every 10,000 hysterectomies. The patient was subjected to hysterectomy, appendectomy and had her obturator and iliac lymph nodes removed. Postoperative treatment comprised radiotherapy. It is estimated that on overall chance of 5 year survival is close to 50%. The overall good state of the patient, 4 years after operation, speaks for recommending this kind of treatment. The authors suggest that the carcinoid does not necessarily must be an inductor of a cancer of the endometrium and they indicate that a cancer of the endometrium is not an inductor of the carcinoid.
Ginekol Pol 2003 Feb
PMID:[Case of carcinoid of the appendix in a patient with endometrial cancer and uterine myoma]. 1271 26

The paper presents a case of abnormal endometrium proliferation detected during routine examinations before the final stage of the in vitro fertilization and embryo transfer program (IVF-ET). Diagnostic excochleation of the uterus histopathologically revealed Ca endometrium.
Ginekol Pol 2003 May
PMID:[Endometrial carcinoma during the IVF program]. 1293 68


<< Previous 1 2 3 4 5 6 7 Next >>